Nurix’s lead candidate, bexobrutideg, has delivered an 83% objective response rate in heavily pretreated relapsed/refractory CLL patients, including complete remissions in 4.3% of the 47‐patient cohort. Median progression-free survival reached 22.1 months, outperforming current BTK inhibitors in a similar setting, while no dose-limiting toxicities were observed across all dose levels. Preclinical studies have shown superior degradation potency against clinically relevant BTK mutations and robust CNS penetration, positioning bexobrutideg as a potential best-in-class degrader with activity in sanctuary sites and an ability to address unmet needs in patients who have failed multiple lines of therapy.

With cash and investments exceeding $650 million, Nurix is funded through 2028, enabling aggressive advancement of its pipeline. Key 2026 objectives include completion of the DAYBreak CLL-201 Phase 2 study at 600 mg once daily and initiation of the confirmatory DAYBreak CLL-306 Phase 3 trial to support global registration in relapsed/refractory CLL. The company also plans an IND submission for bexobrutideg’s new oral tablet formulation in autoimmune and inflammatory indications, and will advance partnered degraders of IRAK4 (with Gilead) and STAT6 (with Sanofi) using its DEL-AI discovery platform to drive additional high-value targets.